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Abstract
New reliable biomarkers are needed for the development of more individualized treatment strategies in
patients with ovarian cancer. The prognostic value of gene polymorphisms in the platelet-derived growth
factor (PDGF) system were investigated in hypothesis-generating patient material followed by a validation in
a second cohort. PDGF-AA 1589 G/T showed prognostic value in the first cohort but failed to demonstrate the
same results in the validation study.
Introduction: New reliable and validated markers are desirable in the treatment of ovarian cancer. The platelet-
derived growth factor (PDGF) system plays an important role in tumor growth and angiogenesis, and high expression
of PDGF/PDGF receptor (PDGFR) has been reported in ovarian cancer. Single nucleotide polymorphisms (SNPs)
within a gene may be important for the function of the protein. This had led to the hypothesis that SNPs within the
PDGF system could have clinical relevance as prognostic biomarkers in ovarian cancer.Methods: The study included
hypothesis-generating patient material from 170 patients with histologically verified epithelial ovarian cancer in which
5 tagging SNPs in the promoter region of the PDGF-AA, PDGF-BB, PDGFR-, and PDGFR- genes were analyzed
by means of SNaPshot Multiplex (Applied Biosystems, Carlsbad, CA) and sequencing methods. The results were
validated in an independent second cohort of 85 patients. Results: In the hypothesis-generating study, survival
analyses were made for all 5 SNPs. PDGF-AA 1589 G/T genotype was found to be associated with overall survival
in univariate analysis (P  .03), with a clear trend seen in Cox multivariate analysis (P  .12; hazard ratio, 0.75).
However, the suggested prognostic importance of PDGF-AA 1589 G/T was not confirmed in the second cohort.
Conclusion: Tagging SNPs in the promoter region of the PDGF-AA, PDGF-BB, PDGFR-, and PDGFR- genes, as
evaluated here, are not likely to be of prognostic importance in patients with ovarian cancer.
Clinical Ovarian & Other Gynecologic Cancer, Vol. 5, No. 1, 10-6 © 2012 Published by Elsevier Inc.
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Epithelial ovarian cancer is associated with severe morbidity and
high mortality rates. Two thirds of the patients are diagnosed with
advanced-stage disease and despite high response rates (80%)1 from
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linical Ovarian & Other Gynecologic Cancer June 2012first-line treatment with surgical debulking and platinum-based che-
motherapy, relapse often occurs within a few years. Retreatment of
the recurrent disease poses considerable problems with limited re-
sponse rates, drug resistance, and chemotherapy-related toxicity.2,3
The 5-year survival rate for patients with advanced-stage disease is
around 30%.4
The development of more individualized treatment strategies may
improve the outcome, and in this connection the identification of
new reliable biomarkers with predictive and/or prognostic value may
prove useful. Furthermore, a better knowledge of the various path-
ways involved in tumor growth is essential for targeting these
pathways.
During recent years, there has been a special focus on the vascular
endothelial growth factor (VEGF) system in relation to ovarian can-
cer because of its importance in angiogenesis.5,6 However, only a
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9minor fraction of patients will benefit from anti-VEGF therapy, and
some only for a relatively short time before tumor progression occurs.
The limitations of the anti-VEGF treatment may be caused by other
proangiogenic factors, among them the platelet-derived growth
factor (PDGF) system.6 Mutual interactions between VEGF and
DGF seem to be of major biological importance, and therefore
urther clarification of the PDGF system is highly warranted.
The PDGF family consists of 5 isoforms; PDGF-AA, PDGF-AB,
DGF-BB, PDGF-CC, and PDGF-DD encoded by 4 different
enes7 and 3 corresponding  and  tyrosine kinase receptors;
DGFR-, PDGFR-, and PDGFR-/.8
PDGF/PDGFR are important to cell growth,9 chemotaxis,9,10
interstitial fluid pressure regulation,11 and tumor stromal modula-
ion including both fibroblast and pericyte recruitment.8,12-15 Spe-
cifically, PDGF-BB/PDGFR- participate in controlling the peri-
yte/endothelial cell interactions,16 and communication between
PDGF-BB/PDGFR- and the structurally related VEGF system is
described in the literature.17-19 In animal models, PDGF-BB has also
een reported to contribute to lymphatic metastases.20 Furthermore,
he expression of PDGF/PDGFR has been demonstrated in ovarian
ancer.21-28
Normal DNA sequence variation (polymorphism) within a gene
may be of functional importance for the protein encoded by the gene,
and therefore single nucleotide polymorphisms (SNPs) could have
clinical relevance as prognostic biomarkers.
Both single SNPs and underlying haplotypes generated from dif-
ferent combinations of SNPs in linkage disequilibrium are stable and
reliable markers, which makes them attractive in clinical studies.
SNPs within the PDGF system have been associated with some
nonmalignant diseases, eg, cardiac allograft vasculopathy (PDGF-
BB),29 risk of neural tube defect (PDGFR-),30 schizophrenia
PDGFR-),31 asthma in children (PDGFR-),32 and cleft lip
(PDGF-CC).33
The possible biological and/or clinical importance of SNPs within
the PDGF system has not been sufficiently elucidated in patients
with cancer. However, in addition to increased focus on the PDGF
system in relation to cancer, studies of PDGF SNPs in, eg, glioblas-
toma, neuroectodermal tumors, leukemia, ovarian cancer, and
esophageal adenocarcinoma have been published in the past few
years.34-39
Therefore our aim was to investigate the possible clinical impor-
tance of SNPs, focusing on the regulatory promoter region of the best
known PDGF genes (PDGF-AA, PDGF-BB, PDGFR-, and
PDGFR-) and compare the gene variations to clinical parameters
nd survival in patients with ovarian cancer. The study included
ypothesis-generating patient material followed by a validation of
ignificant markers in an independent second cohort.
Patients and Methods
Hypothesis Generating Study 1
This study consisted of formalin-fixed, paraffin-embedded tumor
specimens from 170 patients with histologically verified epithelial
ovarian cancer, stage II to IV, who had undergone debulking surgery
from 1991 to 1994. The patients were enrolled in the Danish Ovar-
ian Cancer Study Group (DACOVA) 9101 protocol, approved by
the Danish Biomedical Research Ethics Committee, and written in- fformed consent was obtained from all patients. The patients were
randomized to receive combination chemotherapy with either cyclo-
phosphamide (500 mg/m2) and carboplatin at a dose of area under
he curve  4 (AUC 4) or cyclophosphamide (500 mg/m2) and
carboplatin at a dose AUC 8. No survival difference between the 2
groups was observed.40 All tumor specimens were histologically re-
xamined by a dedicated gynecologic pathologist, using the World
ealth Organization histologic classification, and graded according
o Shimizu et al.41 Further details on this material have previously
been published elsewhere.42 One representative tissue block contain-
ing tumor was selected from each patient and 50-m sections were
cut and stored in Eppendorf tubes at room temperature until further
use.
Validation Study 2
This study included blood samples from 85 newly diagnosed pa-
tients with ovarian cancer, International Federation of Gynecology
and Obstetrics (FIGO) stages II-IV, who were enrolled in a prospec-
tive Danish translational research protocol from March 2005 to May
2010. The protocol was approved by the Danish Biomedical Re-
search Ethics Committee and the Danish Data Protection Agency,
and written informed consent was obtained from all patients. All
blood samples were taken at the time of diagnosis. Combination
chemotherapy with carboplatin and paclitaxel was used as standard
treatment, but a minor fraction of the patients received either carbo-
platin monotherapy (3.5%) or treosulfan (4.7%) as first-line treat-
ment because of poor performance or insufficient kidney function.
Selection of SNPs
Tagging SNPs covering the regulatory promoter region were se-
lected in December 2009 on the basis of a scrutiny of the HapMap
(available at: http://www.hapmap.org/) and the National Center for
Biotechnology Information (NCBI) program (available at: http://
ww.ncbi.nlm.nih.gov/SNP). We excluded SNPs in known linkage
isequilibrium, and the minimum requirement for minor allele fre-
uency in SNPs was 5%.
Analysis of SNPs From Study 1
Genomic DNA was extracted from the 50-m paraffin-embedded
issue sections. After deparaffinization with xylene, tumor tissues
ere washed twice with ethanol. DNA was isolated using the
ucleoSpin Tissue method (NucleoSpin Tissue, Macherey-Nagel,
ermany) according to the user manual.
SNPs were analyzed by the SNaPshot Multiplex method (Applied
iosystems [AB], Foster City, CA), in which the 5 SNPs from the
DGF system were genotyped simultaneously through this multi-
lex primer extension-based method (amplification, single base ex-
ension and detection). Details of SNPs and primer sequences used
or the analysis are listed in Table 1.
Briefly, the procedure was as follows: 0.2-M primers (DNA
Technology A/S, Arhaus, Denmark) for PDGF-AA, PDGF-BB, and
PDGFR-; 0.5-M primers for PDGFR-; 2x Qiagen Multiplex
PCR Master Mix (Qiagen Inc, Valencia, CA); and sterile water were
added to 1 L genomic DNA giving a total of 10 L. The polymer-
se chain reaction (PCR) cycling conditions were 15 minutes at
5°C, 35 cycles (94°C for 30 seconds, 56°C for 90 seconds, and 72°C
or 90 seconds), and 10 minutes at 72°C. Five microliters of this PCR
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12 Cproduct were treated with 2 L ExoSAP-IT (USB Products, Cleve-
and OH) at 37°C for 60 minutes, removing unused primers and
eoxyribonucleotide triphosphates, and at 80°C for 15 minutes to
nactivate ExoSAP. Three microliters of these ExoSAP PCR products
ere then added to 5 L SNaPshot Multlex Ready Mix (AB), 1 L
ooled SNaPshot primer, and 1 L water and run at 96°C for 10
seconds, 25 cycles (50°C for 5 seconds and 60°C for 30 seconds),
after which the product was denatured for 5 minutes at 95°C (a mix
of HI–DI formamide (AB), GeneScan-120 LIZ (Invitrogen, Carls-
bad, CA) and the SNaPshot product). A control reaction of the
SNaPshot procedure was run simultaneously.
When the SNaPshot Multiplex method did not produce readable
results, sequencing of DNA was done by means of BigDye-labeled
terminator cycle sequencing and with the use of sequencing kit (AB).
One microliter ExoSAP-treated PCR product was added to 1.5 L
x BigDye sequencing buffer, 1-L Terminator RR mix, 1 L se-
uencing primer, and water in a final volume of 10L. This mix was
run for 10 seconds at 96°C, 25 cycles (5 seconds at 50°C and 4
minutes at 60°C). The analyses of the products were carried out on
an ABI PRISM 3130 genetic analyzer (AB).
SNP analyses were possible in 162 of the 170 tumor samples
regarding PDGF-BB 1750 A/T, PDGFR- 242 T/C, PDGFR- 182
G/T, and PDGFR- 203 G/T, whereas they were possible in 161 of
he samples regarding PDGF-AA 1589 G/T.
Analysis of SNPs From Study 2
Genomic DNA was isolated from whole blood by Maxwell 16
System DNA Purification Kits (Promega Corp, Madison, WI). The
SNP was analyzed by sequencing as already described. Table 1 shows
the primers used for the PCR.
Statistical Analyses
The 2 test was used to ensure Hardy-Weinberg equilibrium. The
isher exact test or the 2 test was used to test a possible association
between the genotype distribution and clinicopathologic parameters.
Kaplan-Meier estimates were used for univariate overall survival
analysis, and the log-rank test was used to compare the survival plots
between 2 groups. Overall survival was calculated as the interval from
the time of diagnosis until death from any cause. The Cox regression
Table 1 SNPs and Primer Sequences for Multiplex PCR or Seq
SNP rs. nra Forward PrimerSequences
Study 1
PDGFAA 1589 G/T 9719231 CCTTGGAAACGTGGAGGAG C
PDGFBB 1750 A/T 130653 CTGCATTAGGCTGGTTCACA C
PDGFR 242 T/C 6554162 TTTGTTCCCGCTCATTTTCT A
PDGFR 182 G/T 1800812 CGGTGGTACGATTCCTCAAA G
PDGFR 203 G/T 3828610 TCCCCCAAGTTTCTTGTTTTT T
Study 2
PDGFAA 1589 G/T 9719231 ACG TCT CTC CCT TCC GTTG CTT
a SNP ID.
b Basepairs.model was used for multivariate analysis of prognostic parameters.
linical Ovarian & Other Gynecologic Cancer June 2012The checks of proportional hazards assumption seem to indicate that
the assumption holds. A value of P .05 was considered statistically
significant.
Both NCSS (Number Cruncher Statistical System, version
2007, licensed in Kaysville, UT) and Stata 11.0 (Stata Corp LP,
College Station, TX) software packages were used for the statis-
tical analyses.
Results
Patient Characteristics and Clinical Parameters
Table 2 shows patient characteristics and the genotype distribu-
tions of the SNPs in both studies. All PDGF SNPs evaluated were
found to be in Hardy-Weinberg equilibrium.
In study 1, the majority of the patients had FIGO stage III disease
(74%), and most of the patients were diagnosed with serous adeno-
carcinoma (78%). Median age at the time of diagnosis was 56.27
years. At censoring time (November 2010), 22 patients (13%) were
still alive. The median follow-up time for those patients was 18 years.
In study 2, serous adenocarcinoma was also the most frequent
histologic subtype (83%), and the majority of the patients had FIGO
stage III disease (72%) at time of diagnosis. The median age was
66.63 years. Thirty patients (35%) were alive at censoring time (Au-
gust 2011), and the median time of follow-up for these patients was
4.4 years.
No significant associations between the SNP genotype distribu-
tions and clinical parameters were observed, except in patients with
AA genotype PDGF-BB 1750 A/T who were diagnosed with serous
adenocarcinoma more often than patients with the corresponding
genotypes (P  .01), and in patients with TC genotype PDGFR-
242 T/C who were more likely to have FIGO stage III/IV disease
than FIGO stage II (P  .03).
Further calculation of the data for SNP PDGF-AA 1589 G/T
indicated that there were no significant differences in the genotype
distributions between the 2 studies (P  .42).
Prognostic Values of PDGF SNPs
In study 1, survival analyses were made for all 5 SNPs; PDGF-AA
589G/T, PDGF-BB 1750 A/T, PDGFR- 242 T/C, PDGFR- 182
G/T, and PDGFR- 203 G/T. Interestingly, PDGF-AA 1589 G/T
ng Used in Study 1 and Sequencing Used in Study 2
verse Primer
equences bp
b Extension Primer
SnaPshot bp
AGAAGCCATGCAGT 98 (A)20CCTCCAGGGGGAACTT 36
AGCAGGAAGCAAGC 111 (A)25AAGGCTGCATGGAAGG 41
TCGCTATTACTTCCA 122 (A)25CTCGCTATTACTTCCACATGT 46
TGTTTTCGGGGTTAT 97 (A)31TTTTTTTGTATGCGAGATAGAA 51
TCCCCTCACATCCT 84 (A)41GGGAGGGAGTAAGCAGAG 59
AGA AGC CAT GCA GT 203uenci
Re
S
TTTCC
ACCTT
CCGC
CCTT
AAGCA
TCCindicated a possible prognostic importance, as seen in Figure 1 A, in
2w
a
P
(
SNP analysis was technically possible in 161 of the specimens.
b SNP analysis was technically possible in 162 of the specimens.
Christine Vestergaard Madsen et alwhich patients with heterozygousPDGF-AA 1589G/T genotype had
higher survival rates than did their corresponding homozygous ge-
notypes (P  .03). The lower quartile (0.25) of survival time for
patients with GT was 8.5 years (95% CI 5.5-12.4) compared with
3.3 years (95% CI  2.4-4.0) for GG and 3.8 years (95% CI 
.3-5.0) for TT, as also indicated by the Kaplan Meyer plots.
PDGF-AA 1589 G/T was included in the Cox analysis together
ith the classic prognostic parameters: FIGO stage, residual tumor,
ge, grade, and histologic type. The prognostic importance of
DGF-AA 1589 G/T did not hold true in the multivariate analysis
Table 3), but a clear trend was found (P  .12, hazard ratio, 0.75)
Figure 1 A, Overall Survival Curves for the PDGF-AA 1589
SNP Genotype in 161 Patients With Ovarian Cancer,
Study 1. The Red Line Represents Patients With GT
Genotype (n  77), the Black Line Represents
Patients With GG Genotype (n  33), and the Green
Line Represents Patients With TT Genotype (n 
51). B, Validation Cohort From Study 2 Included
85 Patients With Ovarian Cancer. Red Line
Demonstrates Patients With GT Genotype (n  46),
Black Line Represents Patients With GG Genotype
(n  12), and Green Line Represents Patients with
TT Genotype (n  27)
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GGTable 2 Patient Characteristics and SNP Distributions in
Study 1
Patient Characteristics
n  170
Study 1
No. (%)
Study 2
No. (%)
Age (y)
25-59 112 (66) 26 (31)
60-89 58 (34) 59 (69)
FIGO Stage
I 0 (0) 0 (0)
II 28 (16) 12 (14)
III 125 (74) 61 (72)
IV 17 (10) 12 (14)
Histologic Tumor Grade
G1 (well differentiated) 40 (24) 12 (14)
G2 (moderately differentiated) 47 (28) 19 (22)
G3 (poorly differentiated) 68 (40) 47 (55)
Not graded 15 (9) 7 (8)
Histologic Cell Type
Serous 132 (78) 70 (83)
Mucinous 12 (7) 0 (0)
Endometrioid 11 (6) 4 (5)
Clear cell 5 (3) 5 (6)
Undifferentiated 7 (4) 0 (0)
Mixed 3 (2) 6 (7)
Residual Postoperative Tumor
 1 cm 67 (39) 41 (48)
 1 cm 76 (45) 43 (51)
Unknown 27 (16) 1 (1)
SNP PDGF-AA 1589 G/T
(rs 9719231)a
GG 33 (20) 12 (14)
GT 77 (48) 46 (54)
TT 51 (32) 27 (32)
SNP PDGF-BB 1750 A/T
(rs 130653)b
AA 99 (61)
At 53 (33)
TT 10 (6)
SNP PDGFR- 242 T/C
(rs 6554162)b
TT 9 (6)
TC 67 (41)
CC 86 (53)
SNP PDGFR- -182 G/T
(rs 1800812)b
GG 99 (61)
GT 57 (35)
TT 6 (4)
SNP PDGFR- 203 G/T
(rs 3828610)b
GG 16 (10)
GT 68 (42)
TT 78 (48)
acalling for further investigation.
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14 CIn study 2, no differences in survival rates according to PDGF-AA
589 G/T genotypes were observed (Figure 1B). Furthermore,
DGF-AA 1589G/Twas not found to be an independent prognostic
actor in Cox regression analysis (P  .16) (Table 3).
Discussion
New reliable and validated markers are urgently needed in the
treatment of ovarian cancer. The PDGF system participates in tumor
growth and angiogenesis and is a potential target in cancer treat-
ment.6,43,44 The possible prognostic value of the PDGF system in
ovarian cancer has not yet been clarified, but a relation between high
PDGFR expression in ovarian cancer and aggressive tumor behavior
has been reported,22,23,25 and in 2 of the studies high PDGFR-
expression also seemed to have prognostic value.22,23
Genetic changes in the PDGF system can be important in tumor
development, as seen in gastrointestinal stromal tumors (GISTs) in
which mutations in exon 12 or in exon 18 in PDGFR- have been
reported in 1.5% and 5.6% of the GIST tumors, respectively.45
Studies of the closely related VEGF system have indicated that
some SNPs within the VEGF system influence the protein concen-
tration46-48 and seem to hold prognostic information not only in
varian cancer47,49-51 but also in other malignant tumors,52,53 al-
hough the findings appearing in the literature are not consis-
ent.54-56 Therefore it is clearly justified to investigate the possible
Table 3 Multivariate Analysis in Studies 1 and 2
Study 1
Patient Characteristics
n  161
Hazard
Ratio 95% CI
FIGO Stage 0.77-2.43
II 1.00
III  IV 1.76
Grade 1.24-3.09
I 1.00
II  III 1.95
Histologic Type 1.03-2.38
Serous 1.00
Nonserous 1.56
Residual Tumor
1 cm 1.00 0.81-2.07
1 cm 1.30 1.56-4.74
Unknown 2.72
PDGF-AA 1589 G/T 0.52-1.08
Homozygous 1.00
Heterozygous 0.75
Age (Y) 1.24-2.763
25-59 1.00
60-90 1.85
Abbreviation: CI confidence interval.
a One patient was excluded because of missing data.linical significance of SNPs in the related PDGF system. i
linical Ovarian & Other Gynecologic Cancer June 2012The literature on SNPs in the PDGF system related to their
ossible biological and/or clinical importance of cancer is scarce.
specific promoter haplotype in the PDGFR- gene has been
associated with decreased risk of glioblastoma developm-
ent,34 and another promoter haplotype in the PDGFR- gene has
been associated with patients with primitive neuroectodermal tu-
mors and ependymomas.35 SNPs in PDGFR-, and PDGFR-
genes have been investigated in relation to the side effects of imatinib
mesylate treatment in patients with chronic myeloid leukemia. How-
ever, no such association was found.36 In esophageal adenocarci-
oma, several SNPs in theVEGFR, PDGFR-, and PDGFR- genes
and their interactions with body mass index have been found to be
associated with esophageal adenocarcinoma development.39
Recently, 2 studies concerning angiogenic SNPs and ovarian can-
cer have been published. Goode et al investigated a broad panel of
SNPs in genes from different ovarian cancer–related pathways, eg,
angiogenesis in relation to survival for 325 patients with ovarian
cancer.38 SNPs from the PDGFR- and PDGF-D genes were in-
cluded. Variation within angiogenesis was associated with survival,
but PDGFR- and PDGF-D SNPs were not mentioned as specifi-
ally significant in this material.
In the study by Liang et al involving 339 patients with ovarian
ancer and 349 healthy control persons, a panel of SNPs from genes
Study 2
alue Hazard Ration  84a 95% CI P Value
.28 0.92-7.79 .07
1.00
2.67
004 0.67-5.92 .21
1.00
1.99
.04 1.75-7.09 .004
1.00
3.53
1.49-5.51 .0016
.27 1.00
004 2.86
.12 0.85-2.72 .16
1.00
1.51
002 0.51-2.50 .75
1.00
1.13P V
.
.0
.nvolved in microRNA processing and binding sites was investigated
c
t
m
v
c
b
f
t
g
t
b
.
s
t
t
r
h
e
t
e
c
Christine Vestergaard Madsen et alin relation to ovarian cancer risk, survival, and treatment response.37
Variation in PDGF-C genotype was found to be associated with poor
prognosis and worse treatment response.
In our hypothesis-generating study, we found a possible prognos-
tic importance of PDGF-AA polymorphism in patients with ovarian
ancer in univariate analysis and a tendency to independent prognos-
ic value in multivariate analysis, and therefore a validation study was
andatory. However, the same observation was not made in the
alidation cohort. The smaller number of patients in the validation
ohort did not seem to be a reasonable explanation of the discrepancy
ecause there was not even a tendency toward the same survival rates
or the heterozygous patients in studies 1 and 2, as one can see from
he Kaplan-Meier curves in Figure 1. The 2 cohorts were generally
comparable except for age, the patients in cohort 1 being younger
than those in cohort 2. Furthermore, the proportion of patients clas-
sified with unknown postoperative tumor was higher in cohort 1
than in cohort 2.
The phenomenon of loss of heterozygosity (LOH) has been con-
sidered a possible explanation because of the different results ob-
tained from tumor tissue and blood. In fact, LOH has been described
at chromosome 7p.57,58 In our study, the proportion of heterozy-
otes for PDGF-AA 1589G/T in cohort 1 (48%) was a bit lower than
hat in cohort 2 (54%). However, the difference of genotype distri-
ution was not significantly different between the 2 groups (P 
43), indicating that LOH is unlikely to be a major problem in our
tudy.
The present study elucidates a common problem in the investiga-
ion of biomarkers. Most studies are retrospective and include fewer
han 100 patients without validation in independent patient mate-
ial. The risk of a “positive” biomarker being a false positive is very
igh in small trials, as can be seen in the present study. It is therefore
ssential to keep up generally accepted guidelines for biomarker
esting.59
Conclusion
The present study indicates that tagging SNPs in the regulatory pro-
moter region of PDGF-AA, PDGF-BB, PDGFR-, and PDGFR-, as
valuated here, are not likely to be of prognostic importance in ovarian
ancer.
Clinical Practice Points
● There is an obvious need for a better selection of patients with
ovarian cancer for different treatment options based on validated
reliable prognostic markers.
● The PDGF system is important in angiogenesis and for tumor
growth. Many malignant tumors, including ovarian cancer, are
characterized by high levels of PDGF/PDGFR.
● SNP within a gene may be of functional importance to the protein,
and the possible usefulness of SNPs as genetic cancer biomarkers
has led to increased investigation of this area over past decades.
Very few studies have investigated the importance of SNPs in the
PDGF system in relation to malignant tumors.
● We investigated the clinical importance of tagging SNPs in the
promoter region of PDGF-AA, PDGF-BB, PDGFR-, and
PDGFR- in patients with ovarian cancer in hypothesis-generat-
ing patient material, followed by validation of the significant prog-
nostic marker in a second cohort.● We found a correlation between SNP PDGF-AA 1589 G/T and
survival. However, the SNP failed to demonstrate the same prog-
nostic value in the validation study. We therefore believe that
SNPs in the promoter region of PDGF-AA, PDGF-BB,
PDGFR-, and PDGFR- as evaluated in the present study are
unlikely to be of prognostic importance in ovarian cancer.
● In our opinion, this study supplies interesting new information
about SNPs within the PDGF system and ovarian cancer.
● Furthermore, the results from the 2 cohorts support the impor-
tance of validation of small retrospective biomarker studies.
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